Burstein, Harold J.

Systemic Therapy for Estrogen Receptor–Positive, HER2-Negative Breast Cancer

Burstein, H. J. (2020) · New England Journal of Medicine

Breast Cancer Treatment StudiesAdvanced Breast Cancer Therapies

Cited by 316

Predictors of resistance to preoperative trastuzumab and vinorelbine for HER2-positive early breast cancer

Harris, L. N., You, F., Schnitt, S. J., Witkiewicz, A., Lu, X., Sgroi, D., Ryan, P. D., Come, S. E., Burstein, H. J., Lesnikoski, B.-A., et al. (2007) · Clinical Cancer Research

HER2/EGFR in Cancer ResearchBreast Cancer Treatment Studies

Cited by 245

Use of the Peroxisome Proliferator-Activated Receptor (PPAR) γ Ligand Troglitazone as Treatment for Refractory Breast Cancer: A Phase II Study

Burstein, H. J., Demetri, G. D., Mueller, E., Sarraf, P., Spiegelman, B. M., & Winer, E. P. (2003) · Breast Cancer Research and Treatment

Peroxisome Proliferator-Activated ReceptorsBreast Cancer Treatment Studies

Cited by 228

American Society of Clinical Oncology Technology Assessment on the Use of Aromatase Inhibitors as Adjuvant Therapy for Women With Hormone Receptor–Positive Breast Cancer: Status Report 2002

Winer, E. P., Hudis, C., Burstein, H. J., Chlebowski, R. T., Ingle, J. N., Edge, S. B., Mamounas, E. P., Gralow, J., Goldstein, L. J., Pritchard, K. I., et al. (2002) · Journal of Clinical Oncology

Breast Cancer Treatment StudiesEstrogen and related hormone effects

Cited by 200